Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Comment by ready2go1on Mar 22, 2010 4:49pm
289 Views
Post# 16910895

RE: PCA3 ON Panther?

RE: PCA3 ON Panther?I have had the chance over the past 2-3 yrs to speak with one of the analysts that covers GPRO. His optimistic opinion on PCA3 and how it will impact Gen-Probe has always given me comfort during down periods for CUR. He was always someone that was pushing GPRO to move forward and get aggressive bringing pca3 to the market. I have mentioned before that he does not follow CUR but does say that PCA3 will be a winner and he can only imagine the impact it will have on CUR's share price.
     We are getting close and I would expect some type of  release when they complete the FDA trial in April.  I would expect a 30-50% share price move. Between now and than I would like to see us stabilize and make the run to $2.00 just prior to the news.
I read the last poster hoping for a fast track; all I can say to that ,is that the GSK trial was very similar to the current FDA trial Gen-Probe is currently running, so with the 30 published trials, the 4+ year GSK trial and the GPRO's trial, I would look for a quick response from the FDA. PCA3 is coming on at the right time, expect big  #'s out of the gate.
(by the way, it looks as if we can clear out the sell order sitting on some brokers desk with one run.)
Bullboard Posts